Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, Oisín, Marie Healy, Anne, Dayton, Francis, Robinson, Shane, O'Reilly, Niall J., Mahoney, Brian, Arthur, Aisling, Walker, Gavin, Farragher, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Letter to Editors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://www.ncbi.nlm.nih.gov/pubmed/33017904
http://dx.doi.org/10.1016/j.mehy.2020.110110
_version_ 1783559335296630784
author Kavanagh, Oisín
Marie Healy, Anne
Dayton, Francis
Robinson, Shane
O'Reilly, Niall J.
Mahoney, Brian
Arthur, Aisling
Walker, Gavin
Farragher, John P.
author_facet Kavanagh, Oisín
Marie Healy, Anne
Dayton, Francis
Robinson, Shane
O'Reilly, Niall J.
Mahoney, Brian
Arthur, Aisling
Walker, Gavin
Farragher, John P.
author_sort Kavanagh, Oisín
collection PubMed
description Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.
format Online
Article
Text
id pubmed-7361049
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73610492020-07-15 Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19 Kavanagh, Oisín Marie Healy, Anne Dayton, Francis Robinson, Shane O'Reilly, Niall J. Mahoney, Brian Arthur, Aisling Walker, Gavin Farragher, John P. Med Hypotheses Letter to Editors Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19. Elsevier Ltd. 2020-10 2020-07-15 /pmc/articles/PMC7361049/ /pubmed/33017904 http://dx.doi.org/10.1016/j.mehy.2020.110110 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to Editors
Kavanagh, Oisín
Marie Healy, Anne
Dayton, Francis
Robinson, Shane
O'Reilly, Niall J.
Mahoney, Brian
Arthur, Aisling
Walker, Gavin
Farragher, John P.
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
title Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
title_full Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
title_fullStr Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
title_full_unstemmed Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
title_short Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
title_sort inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of covid-19
topic Letter to Editors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://www.ncbi.nlm.nih.gov/pubmed/33017904
http://dx.doi.org/10.1016/j.mehy.2020.110110
work_keys_str_mv AT kavanaghoisin inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT mariehealyanne inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT daytonfrancis inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT robinsonshane inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT oreillyniallj inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT mahoneybrian inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT arthuraisling inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT walkergavin inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19
AT farragherjohnp inhaledhydroxychloroquinetoimproveefficacyandreduceharminthetreatmentofcovid19

Ejemplares similares